Design and topline results of TransCon PTH, a long-acting PTH, phase 2 trial in patients with hypoparathyroidism

• David B. Karpf,
• Sanchita Mourya,
• Aliya Khan,
• Lars Rejnmark

Affiliations

David B. Karpf

Clinical Development, Ascendis Pharma, Inc., Palo Alto, United States; Corresponding author.

Sanchita Mourya

Clinical Development, Ascendis Pharma, Inc., Palo Alto, United States

Aliya Khan

Division of Endocrinology and Metabolism and Geriatrics, McMaster University, Oakville, Canada

Lars Rejnmark

Department of Endocrinology, Aarhus University Medical School, Aarhus, Denmark